Looking back in Diagnosing diseases, Current POCT. Looking into the future. Today epidemics of infectious diseases occur more often and spread both faster and further due to globalization and changes in our lifestyles. One way to meet these biological threats is so-called “Frugal Innovations”, which focus on the development of affordable, rapid, and easy-to-use diagnostics with widespread use. In this context, point-of-care-tests (POCTs), performed at the patient’s bedside, reduce extensive waiting times and unnecessary treatments, and enable effective containment measures. Progress in POCT technology and insights on how to use them allows the handling of more patients most effectively in a shorter time frame and consequently improves clinical outcomes at a lower cost. Looking back on the Conventional diagnostic testing Traditional clinical testing is known as the most commonly applied method in clinics and hospitals all across the world. It is believed that there is no laboratory that has not been encountered in one form or another. Traditional testing provided highly reproducible, quantitative data that makes it an advantageous biotechnological tool in scientific research and clinical diagnosis. Nonetheless, Old testing procedures suffered from certain drawbacks. Different attempts were made for the development of the modified platforms to improve this technique and overcome its shortages. POCT and current situation Time-consuming procedures such as transportation, processing, and aliquoting processes are reduced or even eliminated by bringing every step (sample acquisition, preparation, analysis) directly to the patient’s bedside, thereby creating a more streamlined and faster workflow. Looking into the future. POCT has the potential to reduce global health care costs. The highest demand at present is for developing POCT platforms for resource-limited settings. One of the major challenges is to translate research in the POCT area into affordable products that are available at the periphery of the health care system. Intensive efforts would be required to convert the prototypes into highly reproducible POCT platforms with better performance and cost-effectiveness after scaling up. BIOTIME as POCT manufacturer As a high-tech enterprise specializing in developing, manufacturing, and trading POCT in vitro diagnostic reagents. We build revolutionary products in diagnostics, medical devices that serve you, your family, and your community to lead healthy lives. Our devices and reagents are developed with the aim, which is “Fast is fine, but Accuracy is everything”. Numerous master's and doctoral candidates who have an international background are part of our outstanding team of scientists. Our every product has been built with a Trend-tracking function which provides nurses, physicians, respiratory, and therapists, to be able to trace their patients’ history results and treat them efficiently. We provide constant training programs for our devices, re...

In the afternoon of June 30, the inauguration ceremony of Biotime Biotechnology (Xiamen Biotime Biotechnology co., LTD.) Instrument R&D and Production Center was successfully held. The inauguration ceremony was attended by corporate leaders and R&D team, including Biotime Biotechnology Chairman Zhang Guofeng, Deputy General Manager Huang Jianguo, Deputy General Manager Zhuang Yanghuang and Instrument R&D Director Yin Yandong. At the inauguration ceremony, Zhang Guofeng, Chairman of Biotime Biotechnology, delivered a speech. Mr. Zhang said that the establishment of Instrument R&D and Production Center is another important initiative on the way of Biotime's development, and he hoped that the instrument R&D team would contribute to the high-quality development of biomedical business with the creativity and super execution of keeping up with the times under the new starting point. After that, Yin Yandong, the director of instrument R&D, delivered a speech. Mr. Yin said that in the future, the instrument R&D and production center will continue to be customer-oriented, market demand-oriented, pioneering and enterprising, and do what little one can to help of Biotime. Innovation is the driving force of enterprise development. The establishment of Biotime Biotechnology Instrument R&D and Production Center is not only an important step for the enterprise to adhere to the product as the purpose and innovation as the priority, but also will further promote the progress of enterprise R&D technology, enhance the market competitiveness and business coverage of the enterprise, and contribute to the high-quality development of biomedical business.